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Abstract:
Anxiety is a multi-etiology disorder influenced by both genetic background and environment. To study the impact of a genetic pre-
disposition, we developed a novel mouse model of anxiety using a combination of crossbreeding and behavioral selection. Compari-
son of the transcriptomes from the prefrontal cortex and hippocampus of anxious and control mice revealed that the numbers of
significantly up- and down-regulated genes were modest, comprising approximately 2% of the tested genes. Functional analysis of
the significantly altered gene sets showed that functional groups such as nervous system development, behavior, glial cell differen-
tiation and synaptic transmission were significantly enriched among the up-regulated genes, whereas functional groups such as po-
tassium ion transport, Wnt signaling and neuropeptidergic signaling were significantly enriched among the down-regulated genes.
Many of the identified genes and functional groups have been previously linked to the molecular biology of anxiety, while several
others, such as transthyretin, vasoactive intestinal polypeptide and various potassium ion channels, are novel or not as well described
in this context. Supporting the gene expression data, we also found increased excitability in the hippocampi of anxious mice, which
can be a phenotypic result of decreased potassium channel density. Our transcriptome screen showed that the initiation and/or effect
of anxiety involve multiple pathways and cellular processes. The identified novel genes and pathways could be involved in the mo-
lecular pathogenesis of anxiety and provide potential targets for further drug development.
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Abbreviations: ACE – angiotensin convertase enzyme, ACSF
– artificial cerebrospinal fluid, ADCYAP1 – adenylate cyclase-
activating polypeptide 1, AX – anxious, C – control, cAMP –
cyclic adenosine monophosphate, CARTPT – cocaine and
amphetamine-regulated transcript, CGRP – calcitonin-gene re-
lated peptide, CREB – cAMP response element binding, fEPSP
– field excitatory post synaptic potential, GO – gene ontology,
GRIA1 – glutamate receptor, ionotropic 1, GRM1 – glutamate
receptor, metabotropic 1, GRP – gastrin releasing peptide,
KCNB1 – potassium voltage-gated channel, Shab-related sub-
family, member 1, KCNJ4 – potassium inwardly-rectifying
channel, subfamily J, member 4, KCNQ5 – potassium channel,
voltage gated, KQT-like subfamily, member 5, MAPK – mito-
gen-activated protein kinase, MEA – multi electrode array,
NPY – neuropeptide Y, NT – neurotensin, PDYN – prodynor-
phin, PENK – proencephalin, PCx – prefrontal cortex, QPCR –
quantitative real-time PCR, TBS – theta-burst stimulation, VIP
– vasoactive intestinal polypeptide
Introduction
Anxiety spectrum disorders exhibit a high prevalence
and have a serious medical and socioeconomic impact
in developed countries [2, 21]. The disease is multi-
factorial, requiring an interplay between genetic and
environmental factors. The genetic background of
anxiety has been demonstrated to be polygenic, most
likely involving genes from different cellular pro-
cesses and pathways [53, 58]. The identification of
the individual genes related to anxiety is a challenging
task due to the complex gene interactions that finally
lead to the disease. This complexity is mirrored by the
fact that anxiolytic drugs are effective only in a cer-
tain proportion of patients; approximately 40% of
those treated have limited or no response to these
therapies [16]. Above the molecular organizational
level, the anxiety-related neural circuits are also com-
plex, involving the prefrontal cortex (PCx), thalamus,
the hypothalamic-pituitary-adrenal axis, amygdala
and hippocampus. While the amygdala is central in
the formation of emotional responses, especially fear,
two other regions, the hippocampus and ventromedial
and dorsomedial PCx, are preferentially involved in
the contextualization of the proposed threat and the
learning of aversive behavior [3].
The genetic complexity of the disease, the inherent
biological variability of human patients, and the diffi-
culties in collecting human brain samples make it dif-
ficult to study the molecular mechanisms underlying
anxiety. Although animals can only mimic certain do-
mains of the anxiety-related complex behavioral phe-
notypes seen in humans, the availability of animal tis-
sues and the low genetic variability of inbred mouse
or rat strains make animal models attractive. The se-
lection and crossbreeding of extreme anxiety-related
phenotypes could result in a relatively homogenous
population in which the anxiety-related behavior is
a consequence of the same or similar alterations in the
molecular and neuronal networks of the brain. Ac-
cordingly, we applied a behavioral selection strategy
to construct an animal model in which the mice with
extreme anxiety phenotypes were selected and cross-
bred. Selection was made on the basis of anticipatory
anxiety behavior during the handling procedure.
When mice were moved to another cage, some indi-
viduals always ‘volunteered’ earlier, while others al-
ways moved away from the experimenter. Animals
were separated into two groups, early movers (non-
anxious, control) and late movers (anxious, AX), and
were inbred. After 35 generations, the selected AX
breed displayed significant anxiety relative to the
non-anxious controls in different well-established
anxiety tests, such as the open field, elevated plus
maze and light dark tests [54]. The complex nature of
anxiety requires complex, generally open systems in
order to explore the underlying molecular networks.
DNA microarray technology has been proven to be
highly efficient in describing molecular networks in
complex biological processes, such as development,
immunity, cancer progression [35] and various psy-
chiatric disorders [37]. We used DNA microarrays to
study the anxiety related transcriptome changes in
two relevant brain regions, the PCx and hippocampus,
of AX and control mice. We found several genes and
gene networks that were differentially expressed in
one or both of the studied regions. Several of the iden-
tified genes have been shown previously to be in-
volved in anxiety, while others are new and could pro-
vide valuable targets for future drug discovery.
Materials and Methods
Animal care and handling
Individuals of a non-commercially available inbred
mouse strain (MG15) were maintained at EGIS Phar-
maceuticals Co. (Budapest, Hungary). Mice from the
MG15 strain were crossed with NMRI mice (Charles
River Ltd., Budapest, Hungary), resulting a new
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strain. The behavioral selection was performed on in-
dividuals of this strain as described previously [54].
Experiments were performed on 12 AX and 12 con-
trol male mice 15–17-weeks old. The animals were
kept and the experiments were conducted in confor-
mity with Council Directive 86/609/EEC, the Hun-
garian Act of Animal Care and Experimentation
(1998, XXVIII) and local regulations for the care and
use of animals for research.
RNA preparation, amplification and labeling
Total RNA was purified from each mouse sample (PCx
and hippocampus tissue from each mouse) using an
RNA purification kit (Macherey Nagel, Düren, Ger-
many) according to the manufacturer’s instructions. At
a final concentration of 0.8 U/µl, an RNase inhibitor
(Fermentas, Lithuania) was added to the samples. RNA
quantity was determined using NanoDrop 3.1.0. RNA
samples were stored at –80°C before used. A sample of
the total RNA (1 µg) was amplified with the AminoAl-
lyl MessageAmpTM II aRNA Amplification Kit (Am-
bion, USA) according to the manufacturer’s instruc-
tions. An aliquot of the aminoallyl-modified amplified
RNA (aRNA; 6 µg) was labeled with either Cy5 or
Cy3 dye according to the manufacturer’s instructions
(Ambion, USA) then purified using RNA purification
columns from Macherey Nagel (Düren, Germany). The
dye incorporation rate and the labeled aRNA concen-
tration were detected using NanoDrop 3.1.0. The incor-
poration rate of the samples was 30–60 dye molecules
per 1000 nucleotides.
Microarray hybridization and data analysis
The mouse oligonucleotide microarray (8 × 15,000
format) from Agilent Technologies Inc. (Santa Clara,
CA, USA) was used to determine gene expression
changes. The hybridization was performed with the
Agilent Gene Expression Hybridization kit according
to the manufacturer’s instructions. Each array was
scanned at 543 nm (for Cy3 labeling) or at 633 nm
(for Cy5 labeling) in the Agilent Scanner using the
Extended Dynamic Range function of the ScanArray
software (10% and 100% photomultiplier values).
Twelve different samples from either the hippocam-
pus or the PCx (AX and control) were pooled into
four groups (three RNA samples each) and regarded
as biological replicas. In order to eliminate any distor-
tion caused by the different fluorescent dyes, parallel
dye-swap experiments were carried out from two
pools and regarded as technical replicas. Raw data
were analyzed with the Feature Extraction software
from Agilent Technologies (ver. 9.5.1.1.) and the
two-color gene expression protocol (GE2_v5_95_
Feb07). All the ratios were normalized using the
Lowess normalization method. The two-tailed two-
sample unequal variance Student’s t-test with a two-
fold change cutoff was applied to determine which
genes showed significantly altered expression levels
(GeneSpring GX 10.0.2.). The MIAME formatted mi-
croarray data can be found in the ArrayExpress Ar-
chive (http://www.ebi.ac.uk/microarray-as/ae/) with
the Accession Number: E-MEXP-2603. For func-
tional analysis of the altered genes, Gene Ontology-
based functional grouping was applied using the
DAVID web-based knowledge database [51]. The
Pathway Studio 6.0 (Rockville, MD, USA) and the
STRING web-based software [27] were used for path-
way and network analysis.
Quantitative real-time PCR (QPCR)
In order to validate the microarray data, QPCR was
performed on a RotorGene 3000 (Corbett Research,
Sydney, Australia) using gene-specific primers and
the SybrGreen protocol (Roche Applied Science,
Mannheim, Germany) as described previously [42].
Melting temperature analysis was done after each re-
action to check the quality of the reaction. Relative
expression ratios were calculated as normalized ratios
to the mouse -actin gene. A control sample without
template was used for each PCR run to check for di-
mer formation in the primers. The final relative gene
expression ratios were calculated as - Ct values.
Electrophysiology
Using standard procedures, 350-µm-thick transverse
hippocampal slices were prepared from the brains of
2.5-month-old mice using a McIlwain tissue chopper
(Campden Instruments, Loughborough, UK). Slices
were incubated in standard artificial cerebrospinal
fluid (ACSF) at ambient temperature for 60 min with
95% O  – 5% CO . The composition of the ACSF was
as follows (mM): NaCl, 130; KCl, 3.5; CaCl , 2;
MgCl , 2; NaH PO, 0.96; NaHCO, 24; D-glucose, 10
(pH 7.4). Individual slices were transferred to a 3D-
multi-electrode array (MEA) chip with 60 tip-shaped,
60-µm-high electrodes spaced at 100 µm (Ayanda
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Biosystems, S.A., Lausanne, Switzerland). The slice
was continuously perfused with oxygenated ACSF
(1.5 ml/min at 34°C) throughout the recording ses-
sion. Data were recorded using a standard, commer-
cially available MEA setup (Multi Channel Systems
MCS GmbH, Reutlingen, Germany). The Schaffer-
collateral was stimulated by injecting a biphasic cur-
rent waveform (–100/+100 µs) through one selected
electrode at 0.033 Hz. Care was taken to place the
stimulating electrode in the same region from one
slice to the other. The peak-to-peak amplitudes of
field excitatory postsynaptic potentials (fEPSP) at the
stratum pyramidale and stratum radiatum of CA1
were analyzed. After a 30 min incubation period, the
threshold and the maximum of the stimulation inten-
sity required to evoke responses was determined. For
evoking responses, 30% of the maximal stimulation
intensity was used. Following a stable 15-min control
sequence, the stimulus intensity was continuously in-
creased from 0 to 70 µA in 10 µA steps (Input/Output
curve). Long-term potentiation (LTP) was induced us-
ing a theta-burst stimulation (TBS, 4 × 10 bursts of
4 pulses at 100 Hz) protocol applied at the maximum
stimulation intensity.
Results
Microarray analysis of the PCx and hippocam-
pus transcriptomes in AX and control mice
Twelve animals were sacrificed from the AX and con-
trol groups for transcriptome analysis. Total RNAs
were extracted from the hippocampus and PCx and
pooled so that each pool contained RNAs from 3 ani-
mals. For each brain region, four pooled samples from
AX mice were compared to four pooled samples from
control mice. A dye swap was also incorporated in the
experimental design. Two of the four hybridizations
were performed with Cy5 labeled AX samples, and
the other two were performed with Cy3 labeled AX
samples (Fig. 1). Approximately 15,000 genes from
the transcriptomes of the two brain regions were in-
vestigated using a custom made Agilent oligo mi-
croarray with 15,000 features. In order to obtain reli-
able microarray data, a two-step statistical analysis
was performed. A two-tailed two-sample unequal
variance Student’s t-test was used to determine the
p value that was used to find the significant gene
expression changes. Gene expression ratios with p value
< 0.05 and an AX/control ratio < –2 or > 2 were re-
garded as significant repression or over expression,
respectively, in gene activity. To assess the false dis-
covery rate, the microarray data were also investi-
gated with the Significance Analysis of Microarray
method (SAM) using the MultiExperiment Viewer
software [45]. The analysis showed that 94% and
99% of the hippocampus genes and 72% and 84% of
the PCx genes that were identified as significant by
our statistical analysis were also significantly changed
using SAM with a false discovery rate of 5% and
10%, respectively.
The numbers of significantly up regulated genes in
the AX mice compared to controls were similar in the
two brain regions. Sixty and 51 unique genes were
found to be up-regulated in the PCx and hippocam-
pus, respectively, and 97 genes were up-regulated in
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Fig. 1. Experimental design for mi-
croarray analysis. Twelve animals
each were sacrificed from the AX and
control groups. Individual total RNA
samples from the PCx and the hippo-
campus were pooled so that one pool
contained RNAs from three animals.
For each brain region, four pooled
samples were tested from AX mice
against four pooled samples from con-
trol mice. To control dye bias, a dye
swap was also incorporated in the
experimental design. Two of the four
hybridizations were performed with
Cy5 (red)-labeled AX samples, and
the other two were performed with Cy3
(green)-labeled AX samples (Fig. 1).
HIPPO: hippocampus
both regions (Fig 2A). The numbers of down-
regulated genes were also similar in the two brain re-
gions: 41 and 47 unique genes were found to be
down-regulated in the PCx and hippocampus, respec-
tively, and 64 genes were repressed in both regions
(Fig. 2B). The pattern of gene expression was similar
in the two brain regions. We observed a relatively
high correlation ratio of 0.63 between the up-
regulated genes in the two brain regions, suggesting
that the direction and extent of up-regulation was not
region-specific in the AX brain (Fig. 2C). The pat-
terns of down-regulation in the brain regions were
less correlated, although the observed correlation co-
efficient of 0.31 showed that at least the direction of
down-regulation was similar in the two regions. None
of the genes were up-regulated in one region and
down-regulated in the other (Fig. 2D).
To validate the microarray data, the same RNA
samples that were used for microarray analysis were
used for an extensive QPCR screen. Altogether, 66
and 68 significantly changed genes detected by mi-
croarray were tested by QPCR in the PCx and hippo-
campus. Comparing the microarray and the QPCR
data, the results demonstrated a convincing 0.81 cor-
relation between the two methods. Moreover, of the
134 genes tested, only two (1.49% false positive)
demonstrated expression changes in opposite direc-
tions in the microarray and QPCR (Fig. 3 A, B).
Functional analysis of microarray data
In order to gain information about the general func-
tions of the altered genes, we performed a Gene On-
tology (GO) analysis, using the DAVID web-based
knowledgebase [51]. Generally, DAVID analyzes the
GO terms relating to the significantly altered genes,
identifies the terms that contain multiple genes, and
calculates a significance value for the observed en-
richment in comparison with a background gene set.
Because the directions of gene alterations were gener-
ally similar in the two regions and many altered genes
were shared, we analyzed the up- and down-regulated
genes in toto from both brain regions. The analysis re-
vealed that several of the GO biological function
groups that were significantly enriched in the AX
down-regulated gene set had been previously linked
to anxiety and/or mood disorders (Tab. 1). Among
others, these functional classes included potassium
ion transport, the neuropeptidergic signaling pathway,
nervous system development and the intracellular sig-
naling cascade. The down-regulated gene set was also
automatically mapped into previously described path-
ways using the Pathway Studio software. In accor-
dance with the GO analysis results, the pathway
analysis revealed that the down-regulated genes for
several neuropeptides and the corresponding adeny-
late cyclase–cAMP-MAPK, phosphatidyl-inositol–
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Fig. 2. Comparison of transcriptome
changes in the PCx and hippocam-
pus. Venn diagram of the (A) signifi-
cantly up-regulated and (B) down-
regulated genes in the PCx and hippo-
campus (HIPPO). Correlation between
the average log
 
ratios of (C) induced
and (D) repressed genes in AX PCx
and hippocampus vs. the control brain
regions
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Fig. 3. QPCR validation of microarray data. The pools of RNA from the hippocampus and PCx of AX and control mice were used as templates in the
QPCR reaction. The means ± SD of the AX/control ratio detected by microarray and QPCR are shown for the (A) hippocampus and (B) PCx samples
calcium–calmodulin, protein kinase A, and protein ki-
nase C downstream signaling members could be
grouped into a common pathway (Fig. 4). The up-
regulated AX gene set also contained GO biological
function classes possibly related to the observed AX
phenotype, including nervous system development,
behavior and synaptic transmission (Tab. 1).
The DAVID tissue expression database search showed
that the expression of 63 genes from the down-regulated
gene set had been previously linked to the brain, while 16
had been linked to the brain cortex. Similarly to the
down-regulated genes, the DAVID tissue expression data-
base search indicated that the expression of 40 genes
from the up-regulated gene set had been previously
linked to the brain, and 9 had been linked to the hippo-
campus. In addition to the QPCR data, the parallel ap-
pearance of central nervous system-related functional
categories and tissue expression patterns further vali-
dated our microarray experiments.
The STRING protein-protein interaction database
was used to explore all of the possible connections be-
tween the significantly altered genes (Fig. 5). The inter-
action analysis showed that 93 genes, 61% of the AX
down-regulated gene set, were connected to at least one
other gene. The sub-networks at least partially mirrored
the GO functional classes described above, such as the
Wnt signaling network, the neuropeptidergic network,
phosphatidyl-inositol signaling, the calcium signaling
networks and the potassium channel network. The
STRING analysis also revealed other sub-networks con-
taining immunity-related genes/proteins and Rho-Rac
genes involved in cytoskeleton reorganization and traf-
ficking. The STRING interaction analysis of the AX
up-regulated gene set showed that 75 genes, 36% of the
AX up-regulated genes, are connected to each other. The
extended STRING analysis identified sub-networks re-
lated to iodine-thyroxin metabolism, neuropeptidergic
signaling, the homeobox network, lipid metabolism and
inflammation.
Electrophysiology of hippocampal fEPSP and LTP
The down-regulation of the voltage-gated potassium
channel expression in the AX mice could influence
the properties of network excitation and may lead to
a net increase in neuronal excitability. In order to in-
vestigate this hypothesis, we used in vitro fEPSP re-
cordings from hippocampus slices generated with
a multi-electrode array setup (Fig. 6A). The excitabil-
ity was directly addressed by recording an I/O curve
from control and AX mice. The AX mice exhibited
significantly increased evoked fEPSPs from 30 µA
(500 ± 126 µV for AX mice, n = 4, vs. 325 ± 20 µV
for controls, n = 4; p  0.05). This trend was also ob-
served for the stronger stimulation-evoked fEPSPs
(808 ± 172 µV vs. 472 ± 32 µV at 40 µA, 1057 ± 215
µV vs. 602 ± 44 µV at 50 µA, 1253 ± 252 µV vs. 731
± 57 µV at 60 µA and 1644 ± 532 µV vs. 956 ± 67 µV
at 70 µA, for the AX and control mice, respectively).
The observed enhanced excitation in AX mice
could lead to impaired LTP in the hippocampus.
Therefore, we investigated LTP. The level of theta-
burst stimulation (TBS)-evoked LTP was slightly
larger than the control 60 min after TBS (140 ± 3%
for the AX mice, n = 4 vs. 136 ± 4% for the control,
n = 4; p = 0.08). However, the difference was not sig-
nificant (Fig. 6B).
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Tab. 1. Gene Ontology analysis of microarray data. The significantly
up- and down-regulated genes in the hippocampus and/or PCx of AX
mice were analyzed for significantly enriched GO functional groups
using the DAVID web-based knowledge database. The significantly
enriched (p < 0.05) functional groups that could be related to anxiety
and the corresponding p values are shown
Down-regulated genes in AX mice
Gene Ontology biological function term p value
metal ion transport 2.18  10–5
Wnt receptor signaling pathway 5.34  10–5
potassium ion transport 1.01  10–4
neuropeptidergic signaling pathway 5.74  10–4
intracellular signaling cascade 5.57  10–3
nervous system development 1.47  10–2
regulation of adenylate cyclase activity 1.76  10–2
synaptic transmission 2.73  10–2
Up-regulated genes in AX mice
Gene Ontology biological function term p value
nervous system development 3.58  10–5
behavior 2.06  10–4
neuron differentiation 1.90  10–3
regulation of neuron apoptosis 4.21  10–3
synaptic transmission 2.04  10–2
cell-cell signaling 2.07  10–2
neurite development 2.11  10–2
inorganic anion transport 3.18  10–2
glial cell differentiation 4.21  10–2
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Fig. 4. Molecular network analysis of microarray data. Down-regulation of the neuropeptidergic signaling network in AX mice (See the included
Table for gene symbols and level of down-regulation). The significantly repressed genes are highlighted in blue. The fold changes are aver-
ages of four independent measurements in each tissue
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Fig. 5. Network analysis of microarray data. Interaction analysis of the up- and down-regulated AX gene sets. The significantly altered genes
were analyzed by using the STRING interaction database. The functional groups potentially related to anxiety are highlighted, and the genes
relating to the groups are shown with the fold change of up- and down-regulation in the AX hippocampus and PTX vs. controls. The fold
changes are averages of four independent measurements in each tissue
Discussion
Transcriptome changes in the AX prefrontal
cortex and hippocampus
To investigate the genetic background of anxiety, we
applied selection and further breeding of non-anxious
control and AX mice [54]. We hypothesized that the
resulting clearly distinct phenotypes could provide
a valuable basis to study the molecular networks cor-
related to anxiety [1].
Our transcriptome screen revealed that approximately
2% of the tested genes were significantly altered in at
least one of the brain regions of AX mice compared to
controls. The thorough QPCR validation of the mi-
croarray data showed a high correlation between the
two methods with a low rate of false positives. Func-
tional grouping of the significantly altered genes by
GO or STRING-based analysis revealed several func-
tional gene groups that could be associated with the
development of anxiety in both brain regions. Func-
tional groups, such as neuropeptides and develop-
ment-related groups, contained genes from both the
AX up- and down-regulated gene sets, while the po-
tassium ion channel group and the intracellular signal
transduction group contained predominantly down-
regulated AX genes.
Altered neuropeptides and signaling networks
One of the most prominent gene expression alteration
in both brain regions of the AX mice included numer-
ous neuropeptides and members of neuropeptidergic
signaling, primarily the phosphatidylinositol-calcium,
adenylate cyclase-cAMP-MAPK and calmodulin sig-
naling networks. It is interesting that while neuropep-
tide genes were both up-regulated and down-regu-
lated, the downstream signaling pathway members
were mainly down-regulated. The induced neuropep-
tides included angiotensinogen, calcitonin-gene re-
lated peptide, neurotensin, neurotrophin-3 and gastrin
releasing peptide. These up-regulated AX neuropep-
tides were previously shown to have cerebral loca-
tion- and concentration-dependent positive or nega-
tive effects on fear and anxiety responses [9, 12, 13,
19, 38, 50, 52, 55]. Among the down-regulated AX
neuropeptides, prodynorphin and proencephalin dis-
played an anxiolytic effect in different animal models
and anxiety tests [7, 29, 33, 59]. The connection be-
tween vasoactive intestinal polypeptide (VIP), down-
regulated in AX animals, and anxiety has not been
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Fig. 6. Input/Output curve and LTP recordings of AX and control hippocampi. (A) Input/Output curve recorded from hippocampi of AX and con-
trol mice. Inserts show representative fEPSPs evoked by increasing stimulation intensity (red for AX and black for control mice). Calibration
bars are 25 ms and 1 mV. * Significant difference from the control at p  0.05. (B) LTP in hippocampus of the AX and control mice. Inserts show
representative fEPSPs recorded at the indicated time points. Note the larger fEPSPs in the AX mouse. Calibration bars are 25 ms and 1 mV
well described, but the impact of VIP on behavior was
described previously. VIP has been associated with
learning- and memory-related behavior [20], social
behavior [26], and water and alcohol consumption
[32], all behavioral phenotypes that could be related
to anxiety. PACAP, a neuropeptide structurally related
to VIP, was down-regulated in AX and has also been
shown to have an impact on behavior [43, 56] and
memory retrieval [22]. Neuropeptide Y (NPY), an-
other neuropeptide down-regulated in AX, has been
clearly linked to anxiety behavior [8, 25, 44, 47] and
the central response to benzodiazepine treatment [24,
28]. It is interesting that there could be an inverse cor-
relation between the NPY concentration and the con-
centration of transthyretin, the most highly up-
regulated gene we found in AX mice. It has been pre-
viously shown that the NPY concentration was ele-
vated in the forebrain of transthyretin knock-out mice
[41], indicating a transthyretin-mediated NPY down-
regulation. The down-regulation of several signal
transduction pathways linked to neuropeptidergic net-
works were also observed in AX mice. Interestingly,
these networks seemed to be downstream effectors of
the transduction of VIP-PACAP and NPY. The VIP-
PACAP system uses the phosphatidylinositol–cal-
cium–calmodulin signaling pathways and the adeny-
late cyclase–cAMP-PKA-MAPK networks, while
NPY signals through the phosphatidylinositol–cal-
cium–calmodulin network. The phosphatidylinosi-
tol–calcium signaling converges into the calmodulin-
calmodulin kinase network, which targets, among
others, the cAMP response element binding (CREB)
transcription factor [15]. CREB is a common target of
the two signaling pathways. The adenylate cy-
clase–cAMP signaling also targets CREB through the
MAP-MAPK network [15, 60]. It is noteworthy that,
in addition to the involvement in the CREB pathway,
adenylate cyclase signaling has been associated with
the anxiety phenotype [17, 31, 49]. CREB is a central
transcription factor involved in different behavioral
processes and phenotypes, such as memory [34], in-
duction of LTP [10], synaptic plasticity [36] and de-
pression [4, 40, 57]. The connection between CREB
activity and anxiety has also been previously de-
scribed in different model systems [5, 6]. Overall, our
results indicate that the decreased CREB activation
might be involved in the initiation of anxiety in our
animal model.
Anxiety-related changes of ion channel and
receptor expression
One striking feature of the mRNA expression pattern
was the down-regulation of a large number of ion
channels, particularly potassium ion channels, in AX
mice. The significance of the enrichment of the metal
ion transport GO biological function category was p =
0.00002 with 17 repressed genes, while the potassium
channels category had a significance level of p = 0.0001
with 10 genes down-regulated. Among these chan-
nels, only a few have been characterized functionally
in relation to neural excitability and/or anxiety. The
AX down-regulated potassium channel, the voltage-
gated KQT-like subfamily member 5 (KCNQ5), is
a member of the KCNQ family that encodes the Kv7
potassium channel subunits. Kv7 channels are in-
volved in decreasing excitability [23], and Kv7 chan-
nel openers have been successfully applied in uncon-
ditioned and conditioned rodent models of anxiety
[30]. The down-regulated potassium voltage-gated
channel, Shab-related subfamily member 1 (KCNB1)
potassium channel, is a key mediator of the delayed
rectifier Kv currents regulating neuronal excitability
[39]. The AX down-regulated KCNJ4 potassium
channel has also been shown to play a role in decreas-
ing neural excitability in rat primary striatal cultures
[18]. In addition to the various potassium channels,
the delta subunit of the inhibitory GABA-A receptor
was also down regulated in the AX mice, which also
pointed to an imbalance between inhibition and exci-
tation. In support of the increased excitability hy-
pothesis, both the AMPA type ionotropic glutamate
receptor GRIA1 and the group I metabotropic gluta-
mate receptor GRM1 were found to be up-regulated
in both brain regions in AX mice. The involvement of
ionotropic AMPA glutamate receptors and group I
metabotropic glutamate receptors have also been de-
scribed in different models of anxiety [11, 14].
Altogether, the above-mentioned results high-
lighted the possibility that the neural excitability in
the PCx and hippocampus increased in the AX mice.
We addressed the increased neuronal excitability hy-
pothesis directly using electrophysiology in hippo-
campal slices. The excitability (fEPSP) was signifi-
cantly greater in the AX mice than in the control
strain, illustrating that the changes in the mRNA lev-
els were reflected in the phenotype. However, LTP
was intact, suggesting that higher cognitive functions
were not impaired in the AX mice. Our results indi-
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cate that, in addition to the already described in-
creased amygdalar excitability [46, 48], elevated hip-
pocampal excitability also correlates with the anxiety
phenotype.
Conclusions
In accordance with the multigenic nature of anxiety,
our transcription analysis of the AX hippocampus and
PCx clearly revealed that several genes with different
functions and from various pathways may be involved
in the generation of the observed phenotype. One of
the major questions is whether the observed alteration
of gene expression is a cause or an effect of anxiety.
Most likely, both mechanisms are involved in our
model. Pathways, such as the potassium channel net-
work, the neuropeptidergic system and the corre-
sponding signaling pathways, can have a causative
role in anxiety development, while others, such as the
inflammation-immunity related genes, may be a result
of the stress-related immune function modulation.
Our analysis served as a first screening approach. The
characterization of particular genes in the develop-
ment of anxiety requires more focused studies using
targeted loss of function or gain of function ap-
proaches.
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